Company intelligence / Profile preview

Morphic Therapeutic

Waltham, Massachusetts, United Stateslilly.com ↗

Ownership: Public · MORF
Development stage: Phase 2

Overview

MORF-057, the company's lead candidate, is in Phase 2b clinical trials for ulcerative colitis (EMERALD-2) and Phase 2 trials for Crohn's disease (GARNET). The company was acquired by Eli Lilly in 2024 for approximately $3.2 billion.

Therapeutic areas: GastroenterologyPulmonologyCardiovascularImmunologyOncology
Modalities: Small moleculesoral integrin therapies
Industry: Biotech

Drug pipeline

3 assets

MORF-057

Phase 2

Indications: Ulcerative colitis, Crohn's disease

2 more assets in the full pipeline.

Request access →

Partnerships

Janssen BiotechAbbVieSchrödinger

Financials

Market cap: $2.9B
Total revenue: $0
Enterprise value: $2.2B

Beyond the preview

Go deeper on Morphic Therapeutic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Morphic Therapeutic.

Explore the full profile